Committee for Evidence-based Medicine, Japan Society for Oriental Medicine, Tokyo, Japan.
Department of Medical Oncology, Kanazawa Medical University, Ishikawa 920-0293, Japan.
J Integr Med. 2017 May;15(3):182-185. doi: 10.1016/S2095-4964(17)60347-9.
There had been no standardized rules for citing ethical Kampo products used in clinical trials in journal articles. Although the name of a Kampo manufacturer was described in 77.9% of research articles, the name and ratios of crude drug components of Kampo formulas were not described in 77.5% of these papers. Considering the importance of proper characterization of interventions in the Consolidated Standards of Reporting Trials (CONSORT) checklist, we hereby propose the use of the Standards of Reporting Kampo Products (STORK) website, http://mpdb.nibiohn.go.jp/stork, as a reference for Kampo products. This will provide an official source on the internet for verified information on individual Kampo formulations for citation purposes in clinical research articles.
在期刊文章的临床试验中，引用伦理坎波产品没有标准化的规则。尽管在 77.9%的研究文章中描述了坎波制造商的名称，但在 77.5%的这些文章中没有描述坎波配方的生药成分的名称和比例。考虑到在临床试验报告的统一标准（CONSORT）清单中正确描述干预措施的重要性，我们在此提议使用坎波产品报告标准（STORK）网站，http://mpdb.nibiohn.go.jp/stork，作为坎波产品的参考。这将为互联网上提供一个官方来源，用于在临床研究文章中引用个体坎波配方的经过验证的信息。
